Yee, Karen http://orcid.org/0000-0002-6026-1435
Serrano, Daniel
Kando, Judith
McElroy, Susan L. http://orcid.org/0000-0002-8879-0865
Article History
Accepted: 16 August 2019
First Online: 31 August 2019
Compliance with ethical standards
:
: Dr. Yee is an employee of Shire, a member of the Takeda group of companies, and holds Takeda stock. Dr. Kando is a former employee of Shire, a member of the Takeda group of companies, and holds Takeda stock and Johnson & Johnson stock and/or stock options; she is currently an employee of Tris Pharma (Monmouth Junction, NJ). Dr. Serrano is a former employee of Endpoint Outcomes (Boston, MA); he is currently an employee of Pharmerit International (Bethesda, MD). Dr. McElroy is a consultant to or member of the scientific advisory boards of Avanir, Bracket, F. Hoffmann-La Roche Ltd., Ironshore, Mitsubishi Tanabe Pharma America, Myriad, Novo Nordisk, Otsuka, Shire, and Sunovion. She is a principal or co-investigator on studies sponsored by Allergan, Avanir, Azevan, Brainsway, Marriott Foundation, Medibio, Myriad, National Institute of Mental Health, Novo Nordisk, Shire, and Sunovion. She has been a principal investigator on a study supported by Orexigen Therapeutics. She is also an inventor on US Patent No. 6323,236 B2 (Use of sulfamate derivatives for treating impulse control disorders), and along with the patent?s assignee, University of Cincinnati, Cincinnati, OH, has received payments from Johnson & Johnson, which has exclusive rights under the patent.
: The analyses conducted for this study are based on clinical data from three phase 3 studies. For all studies, protocols were approved by ethics committees and conducted in accordance with International Conference on Harmonisation Good Clinical Practice and the principles of the Declaration of Helsinki.
: All study participants were required to provide written, informed consent before entering the studies.